company background image
APLT logo

Applied Therapeutics NasdaqGM:APLT Stock Report

Last Price

US$0.87

Market Cap

US$102.4m

7D

-24.6%

1Y

-72.2%

Updated

23 Dec, 2024

Data

Company Financials +

Applied Therapeutics, Inc.

NasdaqGM:APLT Stock Report

Market Cap: US$102.4m

APLT Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. More details

APLT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Applied Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Applied Therapeutics
Historical stock prices
Current Share PriceUS$0.87
52 Week HighUS$10.62
52 Week LowUS$0.78
Beta1.72
1 Month Change-91.00%
3 Month Change-89.31%
1 Year Change-72.22%
3 Year Change-91.08%
5 Year Change-96.92%
Change since IPO-90.78%

Recent News & Updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Applied Therapeutics: Pushing Towards FDA Approval

Sep 04

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16
Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Nov 13
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Aug 11
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

May 19
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11
Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26
Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18
How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24
Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Applied Therapeutics EPS misses by $0.21

Nov 12

Shareholder Returns

APLTUS BiotechsUS Market
7D-24.6%-3.8%-2.7%
1Y-72.2%-2.6%23.4%

Return vs Industry: APLT underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: APLT underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is APLT's price volatile compared to industry and market?
APLT volatility
APLT Average Weekly Movement24.0%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: APLT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: APLT's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201637Les Funtleyderwww.appliedtherapeutics.com

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.

Applied Therapeutics, Inc. Fundamentals Summary

How do Applied Therapeutics's earnings and revenue compare to its market cap?
APLT fundamental statistics
Market capUS$102.41m
Earnings (TTM)-US$187.31m
Revenue (TTM)n/a

-475.7x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APLT income statement (TTM)
Revenue-US$212.00k
Cost of RevenueUS$52.35m
Gross Profit-US$52.56m
Other ExpensesUS$134.75m
Earnings-US$187.31m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.61
Gross Margin24,794.34%
Net Profit Margin88,353.77%
Debt/Equity Ratio0%

How did APLT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:34
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Applied Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Carter GouldBarclays
Catherine SeifertCFRA Equity Research